camptothecin has been researched along with Carcinoma, Squamous Cell in 167 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.60) | 18.7374 |
| 1990's | 28 (16.77) | 18.2507 |
| 2000's | 83 (49.70) | 29.6817 |
| 2010's | 53 (31.74) | 24.3611 |
| 2020's | 2 (1.20) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, HB; Fan, Z; Fong, HH; Pezzuto, JM; Sun, H; Tan, GT; Zhang, H | 1 |
| Altwerger, G; Azodi, M; Bellone, S; Bianchi, A; Bonazzoli, E; Buza, N; Han, C; Huang, GS; Hui, P; Lopez, S; Manara, P; Manzano, A; Menderes, G; Perrone, E; Ratner, E; Santin, A; Schwartz, PE; Silasi, DA; Tymon-Rosario, J; Zammataro, L; Zeybek, B | 1 |
| Girardi, M; Griff, S; Hu, JK; Lee, AK; Lewis, JM; Moscato, ZM; Qureshi, M; Saltzman, WM; Suh, HW; Yaqoob, S; Yin, ES | 1 |
| Bueno, R; Catalano, PJ; Enzinger, PC; Hong, TS; King, BL; Mamon, HJ; Martin, NE; Sanford, NN; Wo, JY | 1 |
| Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N | 1 |
| Choi, HS; Kim, YK; Yun, PY | 1 |
| Chen, H; Jiang, L; Li, K; Liu, S; Meng, Z; Xia, C; Xu, K; Yuan, D; Zhang, B | 1 |
| Abe, T; Fukaya, M; Itatsu, K; Nagino, M; Yokoyama, Y | 1 |
| Chen, CH; Chen, WS; Cheng, AN; Fan, CC; Huang, TS; Jiang, SS; Kuo, CY; Lee, AY; Lee, CC; Liu, YL; Lo, YK; Wang, TY | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Kadoya, N; Munemoto, M; Murata, S; Saito, H; Yoshimoto, K | 1 |
| Abou Taleb, H; Baba, T; Hamanishi, J; Kido, A; Konishi, I; Matsumura, N; Togashi, K; Yamaguchi, K; Yamanoi, K; Yoshioka, Y | 1 |
| Cominetti, D; De Cesare, M; Lauricella, C; Pisano, C; Veronese, SM; Zaffaroni, N; Zuco, V; Zunino, F | 1 |
| Asaoka, T; Fujitani, K; Hirao, M; Ikeda, M; Ikenaga, M; Miyamoto, A; Nakamori, S; Sekimoto, M; Takeoka, T; Yamamoto, K | 1 |
| Kagabu, M; Kumagai, S; Miura, F; Omi, H; Sato, A; Shoji, T; Sugiyama, T; Takatori, E; Takeuchi, S; Yoshizaki, A | 1 |
| Asamura, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Tamura, T; Tanaka, A; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Kamei, T; Miwa, I; Nakamura, Y; Sakamoto, Y; Shinagawa, M | 1 |
| Ino, K; Kobayashi, A; Mabuchi, Y; Minami, S; Tanizaki, Y; Yahata, T | 1 |
| Cassinelli, G; De Cesare, M; Lanzi, C; Zaffaroni, N; Zuco, V | 1 |
| Cai, Q; Shao, N | 1 |
| Hosomi, Y; Igawa, S; Iwasawa, S; Katono, K; Kishi, K; Kondo, T; Kurimoto, R; Masuda, N; Murakami, S; Ohba, M; Okamoto, H; Oshita, F; Saito, H; Shimokawa, T; Takagi, Y; Takiguchi, Y; Watanabe, K; Yamada, K; Yamamoto, M | 1 |
| Abiko, K; Abou-Taleb, HA; Baba, T; Hamanishi, J; Horikawa, N; Kitamura, S; Konishi, I; Koshiyama, M; Matsumura, N; Murakami, R; Taha, AA; Yamaguchi, K; Yamanoi, K | 1 |
| Chang, PM; Chen, SC; Yang, MH | 1 |
| Benson, AB; Burtness, BA; Cohen, SJ; Douglas, K; Enzinger, PC; Goldberg, RM; Ilson, DH; Mayer, RJ; Niedzwiecki, D; Venook, A; Villaflor, VM; Ye, X | 1 |
| Motoshita, J; Nakagawa, T; Nakano, T; Nakashima, T; Okabe, M; Shiratsuchi, H; Tamae, A; Tanaka, R; Yasumatsu, R | 1 |
| Dahlstrom, KR; Gao, F; Han, P; Li, G; Liu, H; Liu, Z; Owzar, K; Sturgis, EM; Wei, Q; Zevallos, JP | 1 |
| Byer, J; Chang, YD; Kim, DW; Kim, RD; Kothari, N; Mahipal, A | 1 |
| Choi, HG; Choi, JY; Din, FU; Kim, DS; Kim, DW; Kim, JO; Ku, SK; Mustapha, O; Oh, KT; Thapa, RK; Yong, CS; Youn, YS | 1 |
| Bhattacharya, A; Cao, S; Chintala, S; Durrani, FA; Rustum, YM; Slocum, HK; Tóth, K | 1 |
| Enomoto, T; Fukutsuji, K; Ikeda, H; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T; Shibano, A; Yamanishi, M | 1 |
| Kim, MJ; Kim, YK; Lee, JH; Myoung, H; Ok, YJ; Yun, PY | 1 |
| Castellano, V; Moreno, F; Ruiz-Casado, A | 1 |
| al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW | 1 |
| Assersohn, L; Brown, G; Chong, G; Costello, C; Cunningham, D; Higgins, L; Leary, A; Norman, AR; Oates, J; Ross, PJ | 1 |
| Brand, S; Czarnota, GJ; Foster, DB; Kolios, MC; Solanki, B | 1 |
| Hasegawa, K; Kokawa, K; Konishi, I; Nishida, M; Nishimura, R; Noguchi, H; Saji, F; Takizawa, K; Umesaki, N; Yamamoto, K | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Burtness, B; Egleston, B; Forastiere, AA; Gibson, M; Lacy, J; Mehra, R; Murren, JR; Quintanilla, M; Sipples, R; Thomas, L; Watkins, S | 1 |
| Bando, Y; Kenzaki, K; Kondo, K; Miyoshi, T; Ohnishi, Y; Sawada, N; Seike, J; Takizawa, H; Tangoku, A; Yamai, H; Yoshida, T | 1 |
| Argiris, A; Axelrod, R; Brockstein, B; Buchanan, A; Forastiere, A; Ghebremichael, M; Hahn, K; Kolesar, J; Pins, M | 1 |
| Bucci, F; Cincinelli, R; Croce, AC; Favini, E; Pisano, C; Supino, R; Tortoreto, M; Zuco, V; Zunino, F | 1 |
| Benedetti, V; Zuco, V; Zunino, F | 1 |
| Cao, S; Chintala, S; Durrani, FA; Jensen, RL; Rustum, YM; Tóth, K; Vaughan, MM | 1 |
| Blair, EA; Haraf, DJ; Pederson, AW; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Abbas, A; Bekaii-Saab, T; Burak, W; Lustberg, MB; Lustberg, ME; McCracken-Bussa, B; Otterson, G; Villalona-Calero, MA; Young, D | 1 |
| Bastos, BR; Gomez, J; Hatoum, GF; Lopes, G; Raez, LE; Santos, ES; Takita, C; Tolba, K; Walker, GR | 1 |
| Chen, XL; Chen, ZW; Ding, Y; Feng, H; Jiang, S; Wang, Q; Wang, QM; Zhen, MC; Zhu, LJ | 1 |
| Chen, E; Darling, G; Guindi, M; Haider, M; Horgan, AM; Hornby, J; Keshavjee, S; Knox, JJ; Ringash, J; Visbal, AL; Wong, R; Xu, W | 1 |
| Aoe, K; Hayashi, H; Hotta, K; Kawai, H; Kiura, K; Maeda, T; Matsuo, K; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| Aguero, EG; Harper, JL; Kearney, PL; Reed, CE; Ruppert, BN; Sharma, AK; Sherman, CA; Shirai, K; Watkins, JM; Zauls, AJ | 1 |
| Fukui, M; Matsumoto, M; Omasa, M; Shikuma, K; Taki, T; Tomiyama, K; Ueda, Y; Yutaka, Y | 1 |
| Apolloni, C; Ditto, A; Frigerio, L; Melpignano, M; Panici, PB; Pignata, S; Raspagliesi, F; Scambia, G; Scollo, P; Selvaggi, L | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Honda, T; Kondo, T; Murakami, S; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Li, Y; Liu, J; Ren, Y | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Chung, WY; Hwang, SC; Kim, YS; Lee, HL; Lee, KB; Lee, KS; Park, JH; Park, KJ; Sheen, SS | 1 |
| Cai, JF; Chen, B; Lu, HY; Ma, SL; Su, D; Sun, WY; Wang, Z; Zhang, YP; Zheng, YQ | 1 |
| Bai, T; Kobayashi, A; Matsuoka, T; Sasaki, N; Tanaka, J; Tanaka, T; Tanizaki, Y; Toujima, S; Utsunomiya, H; Utsunomiya, T; Yamamoto, M; Yukawa, K | 1 |
| Fujii, M; Hamada, N; Hosokawa, S; Hotta, K; Ichihara, E; Ikeda, G; Kiura, K; Kuyama, S; Nogami, N; Osawa, M; Oze, I; Segawa, Y; Shibayama, T; Tabata, M; Tada, A; Takata, S; Takigawa, N; Tamaoki, A; Tanimoto, M; Uno, M | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Abbruzzese, JL; Beeker, T; Benedetti, JK; Blanke, CD; Gold, PJ; Goldman, BH; Lenz, HJ; Mehta, V; Thomas, CR; Tomblyn, MB | 1 |
| Hiura, M; Kiguchi, K; Kita, T; Kokawa, K; Kubushiro, K; Mizutani, K; Nishimura, R; Sugiyama, T; Takizawa, K; Yaegashi, N; Yamaguchi, S; Yamamoto, K | 1 |
| Hirota, S; Inoue, K; Ito, Y; Kanazawa, R; Komori, S; Maeda, H; Tsubamoto, H | 1 |
| Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C | 1 |
| Aoki, D; Banno, K; Kisu, I; Kobayashi, Y; Masuda, K; Nomura, H; Susumu, N; Tominaga, E; Tsuji, K; Ueki, A; Yamagami, W; Yanokura, M | 1 |
| Amano, O; Hashimoto, K; Hirano, K; Kishino, K; Sakagami, H; Shimada, J; Tamura, N | 1 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P | 1 |
| Chen, HZ; Chen, Y; Ding, XQ; Kong, QY; Wang, AX | 1 |
| Artal, A; Balcells, M; Barneto, I; Cardenal, F; Carrato, A; Domine, M; Felip, E; Garrido, P; Juan, O; López-Vivanco, G; Massutí, B; Rosell, R | 1 |
| Chai, LP; Su, ZZ; Xian, ZX | 1 |
| Hinkelbein, W; Mühr-Wilkenshoff, F; Ohnesorge, I; Riecken, EO; Scherübl, H; Wolf, KJ; Zeitz, M | 1 |
| Vigneswaran, N; Wu, J; Zacharias, W | 1 |
| Charuchinda, C; Chitapanarux, I; Lorvidhaya, V; Pukanhapan, N; Sukthomya, V; Tonusin, A | 1 |
| Artru, P; De Gramont, A; Krulik, M; Louvet, C; Nahon, P; Tournigand, C | 1 |
| Chanslip, Y; Pattaranutaporn, P; Suntornpong, N; Thephamongkhol, K | 1 |
| Araya, Y; Fujimoto, T; Inoue, S; Kameyama, M; Kanetoshi, A; Ohtsuka, K; Shida, A; Takaoka, K | 1 |
| Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C | 1 |
| Abe, S; Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Benedicic, Ch; Petru, E; Pickel, H; Seewann, A | 1 |
| Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH | 1 |
| Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS | 1 |
| Azrak, RG; Cao, S; Durrani, FA; McLeod, HL; Pendyala, L; Rustum, YM; Slocum, HK; Tóth, K; Yin, MB; Zhang, W | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| Kawada, K; Kawano, T; Miyake, S; Nagai, K; Nakajima, Y; Nishikage, T; Ogiya, K; Tanaka, K; Toukairin, Y | 1 |
| Ajani, JA; Cohen, DS; Faust, J; Komaki, R; Lynch, PM; Morris, J; Nivers, R; Putnam, JB; Roth, JA; Smythe, R; Swisher, SG; Vaporciyan, A; Walsh, G; Wu, TT | 1 |
| Dwarakanath, BS; Khaitan, D; Ravindranath, T | 1 |
| Blessing, JA; McGehee, R; Monk, BJ; Muggia, FM | 1 |
| Fujii, T; Fushiki, H; Hasegawa, K; Izumi, R; Nishida, M; Nishimura, R; Takizawa, K; Tanaka, T; Umesaki, N; Yamamoto, K | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Fujiwara, Y; Fukushima, S; Hirohashi, K; Lee, S; Morimura, K; Osugi, H; Suehiro, S; Takemura, M | 1 |
| Baron, B; Bloch, J; Borner, M; Chollet, P; Degardin, M; Dittrich, C; Duffaud, F; Fumoleau, P; Lacombe, D; Rolland, F; Vermorken, JB | 1 |
| Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K | 1 |
| Ilson, DH | 1 |
| Murphy, BA | 1 |
| Azrak, RG; Cao, S; Durrani, FA; Li, X; McLeod, HL; Pendyala, L; Rustum, YM; Shannon, WD; Smith, PF; Yu, J | 1 |
| Berdzik, J; Creaven, PJ; Hoffman, JL; Intengan, ME; Javle, MM; Khushalani, N; Litwin, AM; Pendyala, L; Ramnath, N; Rustum, YM; Slocum, HK; Smith, PF; Stewart, CC; Toth, K | 1 |
| Chen, D; Chen, Y; Ding, XQ; Li, S; Wang, AX | 1 |
| Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Chen, SY; Chen, TH; Gu, MJ; Ma, D; Song, XJ; Wang, CY; Zhang, QH; Zhu, T | 1 |
| Bucana, CD; Carter, KB; Jasser, SA; Kim, S; Myers, JN; Wang, Z; Yazici, YD | 1 |
| Kokawa, K; Tanaka, T; Umesaki, N | 1 |
| Clark, SL; Fong, SE; Koeppen, H; Polakis, P; Ross, S; Rubinfeld, B; Smith, V; Upadhyay, A | 1 |
| Lane, D | 1 |
| Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Frank, C; Hapke, G; Li, ZR; Rustum, YM; Tóth, K; Yin, MB | 1 |
| Bai, T; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Abbruzzese, JL; Atkins, JN; Blanke, CD; Dakhil, SR; Gandara, DR; McCoy, SA; Paradelo, JC; Williamson, SK; Yost, KJ | 1 |
| Kawashima, O; Morishita, Y; Nagashima, T; Sugano, M | 1 |
| Chun, JH; Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY | 1 |
| Adenis, A; Boucher, E; Dahan, L; Di Fiore, F; Galais, MP; Hamidou, H; Hellot, MF; Jacob, JH; Michel, P; Mirabel, X; Paillot, B; Prod'homme, S; Raoul, JL | 1 |
| Kamoto, T; Kawahara, T; Nishiyama, H; Ogawa, O; Yamamoto, S | 1 |
| Furuhashi, S; Hirota, M; Ichihara, A; Kihara, S; Shimada, S; Sugita, H | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Hashimoto, T; Izumi, Y; Kato, T; Kawada, K; Miura, A; Momma, K; Oota, M | 1 |
| Hoff, PM; Phan, LK | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Yoon, SJ | 1 |
| Chen, D; Chen, Y; Ding, XQ; Li, S; Wang, AX; Wang, J | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Takatani, H; Tsukamoto, K | 1 |
| Caponigro, F; Cartenì, G; Davis, WB; Droz, JP; Milano, A; Pollard, P | 1 |
| Honda, M; Imutsuka, S; Korenaga, D; Nozoe, T; Yasuda, M | 1 |
| Iino, K; Morita, M; Sasaki, H; Tomita, K; Toyoshima, H | 1 |
| Aitini, E; Amoroso, V; Ardizzoia, A; Bajetta, E; Bandera, M; Bidoli, P; Cortinovis, D; Cullurà, D; Fusi, A; Lorusso, V; Radula, D; Zilembo, N | 1 |
| Bodrogi, I; Collette, L; Kerst, JM; Leahy, M; Marréaud, S; Oliver, RDT; Skoneczna, I; Theodore, C; Ven, K | 1 |
| Aulicino, C; Benedetti, V; Bucci, F; Carminati, P; De Cesare, M; Foderà, R; Penco, S; Pisano, C; Vesci, L; Zuco, V; Zunino, F | 1 |
| Aulino, JM; Burkey, BB; Chung, CH; Cmelak, A; Gilbert, J; Murphy, BA; Netterville, J; Shyr, Y; Sinard, RJ; Yarbrough, WG | 1 |
| Giovanella, BC; Kozielski, AJ; Mendoza, J; Potmesil, M; Stehlin, JS; Vardeman, D | 1 |
| Esaki, T; Fujishima, H; Masumoto, N; Nakano, S; Niho, Y; Tatsumoto, T | 1 |
| Itoh, K; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Morino, H; Nakagawa, K; Negoro, S; Takada, M; Takifuji, N | 1 |
| Ara, G; Boscia, RE; Holden, SA; Korbut, T; Teicher, BA | 1 |
| Kanematsu, T; Kawanami, K; Kohno, K; Kuwano, M; Taniguchi, K; Wada, M | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM | 1 |
| Eisenhauer, EA; Vermorken, JB | 1 |
| Abe, S; Fujita, A; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Noda, K; Oshita, F; Saijo, N; Suzuki, S; Takahashi, S; Tamura, T; Tobise, K; Tsuchiya, S | 1 |
| Edwards, CL; Ende, K; Fishman, A; Freedman, RS; Hord, M; Kaplan, AL; Kavanagh, JJ; Kieback, D; Kudelka, AP; Levy, T; Llerena, E; Steger, M; Verschraegen, CF | 1 |
| Heuser, A; Sauer, R | 1 |
| Ensley, JF; Lew, D; Rodriguez, GI; Schuller, D; Smith, RE; Taylor, SA | 1 |
| Robert, F; Soong, SJ; Wheeler, RH | 1 |
| Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y | 1 |
| Bailey, H; Durivage, HJ; Gelder, M; Irvin, WP; Potkul, RK; Price, FV; Rosenbluth, R | 1 |
| Chang, L; Ogita, S; Tanaka, T; Umesaki, N | 1 |
| Blessing, JA; Chafe, W; Kohler, M; Levenback, C; Look, KY; Roman, LD | 1 |
| Honda, T; Koizumi, T; Kubo, K; Sekiguchi, M; Takamizawa, A | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Nakajima, T; Negoro, S; Okishio, K; Tada, T; Takada, M; Takeda, K; Tanaka, M | 1 |
| Lad, TE; Minami, H; Nicholas, MK; Ratain, MJ; Vokes, EE | 1 |
| Ekimoto, H; Mashiba, H; Matsumoto, S; Okamoto, K | 1 |
| Fujiyoshi, K; Hiura, M; Kumagai, S; Nishida, T; Nishio, S; Okura, N; Sugiyama, T; Umesaki, N; Yakushiji, M | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Chauvergne, J; Chevallier, B; Dieras, V; Fargeot, P; Fumoleau, P; Krakowski, Y; Lentz, MA; Lhommé, C; Matthieu-Boué, A; Mignard, D; Misset, JL; Rebattu, P; Roche, H; Van Glabbeke, M; Vennin, P | 1 |
| DeGroff, J; Enzinger, P; Gollub, M; Gonzalez, G; Huang, Y; Ilson, DH; Kelsen, DP; Kornblith, A; O'Reilly, E; Saltz, L; Schwartz, G | 1 |
| Azrak, RG; Cao, S; Guo, B; Rustum, YM; Tóth, K | 1 |
| Arimoto, J; Bessho, T; Furukawa, T; Hirai, I; Maebeya, S; Matsuyama, K; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yano, T; Yoshimasu, T | 1 |
| Arietta, R; Brockstein, B; Keubler, JP; Lad, T; Rosen, F; Sciortino, D; Vokes, E | 1 |
| Koshiishi, H; Takahashi, E; Tamamoto, F; Utsumi, K | 1 |
| Fujishiro, M; Fukuda, H; Fukuda, M; Kunitoh, H; Nishiwaki, Y; Ohe, Y; Saijo, N; Sekine, I; Shinkai, T; Tamura, T | 1 |
| Hasuo, Y; Kamura, T; Nishida, T; Sugiyama, T | 1 |
| Donato, NJ; Ling, YH; Perez-Soler, R | 1 |
| Burkey, B; Cmelak, A; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y; Smith, W | 1 |
| Ando, N; Shih, CH | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Adamson, RH; Mead, JA; Sieber, SM | 1 |
| Fukuoka, M; Furuse, K; Hara, N; Hasegawa, K; Nakai, H; Nakao, I; Ogura, T; Saito, H; Sakata, Y; Yoshimori, K | 1 |
| Fukuoka, M; Hasegawa, K; Kimura, M; Kurita, Y; Kuriyama, T; Motomiya, M; Nakabayashi, T; Negoro, S; Niitani, H; Suzuki, A | 1 |
| Aonuma, M; Furuta, T; Kawato, Y; Matsumoto, K; Yasuoka, M; Yokokura, T | 1 |
| Slichenmyer, WJ; Von Hoff, DD | 1 |
13 review(s) available for camptothecin and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
[A case of neuroendocrine cell carcinoma of the esophagus with lung metastases successfully treated with CPT-11/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy | 2013 |
Primary combined small cell carcinoma and squamous cell carcinoma of the oropharynx with special reference to EGFR status of small cell carcinoma component: Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; ErbB Receptors; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasms, Complex and Mixed; Oropharyngeal Neoplasms; Otorhinolaryngologic Surgical Procedures | 2017 |
Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pilot Projects; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Palliative cytostatic treatment of cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Mitomycin; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Survival Analysis; Uterine Cervical Neoplasms; Vindesine | 2003 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.
Topics: Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan | 2005 |
New drugs in gynecologic oncology.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Platinum Compounds; Uterine Cervical Neoplasms | 1996 |
[Topoisomerase I inhibitor with potential radiosensitizing effect].
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan | 1997 |
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Irinotecan; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2001 |
[Chemotherapy for the patients with esophageal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel | 2002 |
Pharmacology of antitumor agents from higher plants.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aporphines; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Etoposide; Humans; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Maytansine; Melanoma; Naphthoquinones; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Experimental; Phenanthrenes; Structure-Activity Relationship; Teniposide; Vinblastine; Vincristine | 1976 |
New natural products in cancer chemotherapy.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan | 1990 |
62 trial(s) available for camptothecin and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds | 2015 |
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Tegafur; Uracil | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Time Factors; Treatment Failure | 2016 |
EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; ErbB Receptors; Female; Florida; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Panitumumab; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2017 |
[Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Platinum; Taxoids | 2008 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Mesothelioma; Middle Aged; Mitomycin; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate | 2009 |
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Uterine Cervical Neoplasms | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Docetaxel; Drug Administration Schedule; Female; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Conformal | 2010 |
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate | 2012 |
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Thoracic Neoplasms | 2012 |
Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Uterine Cervical Neoplasms; Young Adult | 2012 |
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2003 |
A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Survival Analysis | 2003 |
Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2003 |
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Survival Rate | 2003 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2004 |
Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 2004 |
Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prospective Studies; Uterine Cervical Neoplasms | 2004 |
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 2004 |
Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Time Factors | 2004 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclin A; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Respiratory Tract Neoplasms; S Phase | 2005 |
Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Uterine Cervical Neoplasms | 2005 |
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2006 |
Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deglutition Disorders; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome | 2006 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate | 2008 |
Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2007 |
Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2008 |
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Feasibility Studies; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Penile Neoplasms; Time Factors; Treatment Outcome | 2008 |
Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2008 |
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome | 1996 |
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Incidence; Irinotecan; Middle Aged; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 1997 |
Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Topotecan | 1996 |
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Remission Induction; Survival Analysis; Topotecan | 1997 |
A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Patient Satisfaction; Pilot Projects; Platinum Compounds; Remission Induction; Safety; Uterine Cervical Neoplasms; Vomiting | 1998 |
A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 1998 |
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Treatment Outcome | 1999 |
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Glioma; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged | 1999 |
Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Uterine Cervical Neoplasms | 1999 |
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 1999 |
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Deglutition Disorders; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Survival Analysis; Treatment Outcome | 1999 |
Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged | 2000 |
[Evaluation of bronchial arterial infusion (BAI) for high risk lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2000 |
Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2000 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
[A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Vomiting | 1991 |
93 other study(ies) available for camptothecin and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Pseudoirroratin A, a new cytotoxic ent-kaurene diterpene from Isodon pseudo-irrorata.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Diterpenes; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Female; Humans; Inhibitory Concentration 50; KB Cells; Lamiaceae; Lung Neoplasms; Male; Molecular Conformation; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Osteosarcoma; Ovarian Neoplasms; Plants, Medicinal; Prostatic Neoplasms; Spectrophotometry, Ultraviolet; Stereoisomerism; Tumor Cells, Cultured | 2002 |
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Female; Humans; Immunoconjugates; Uterine Cervical Neoplasms | 2020 |
Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles.
Topics: Adhesives; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Glycerol; Mice; Mice, Inbred C57BL; Nanoparticles; Polyesters; Polymers; Skin Neoplasms | 2021 |
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Readmission; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Young Adult | 2017 |
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2018 |
The role of p53 status on the synergistic effect of CKD-602 and cisplatin on oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; Epithelial Cells; Humans; Mouth Neoplasms; Tumor Suppressor Protein p53 | 2019 |
CDKL1 promotes the chemoresistance of human oral squamous cell carcinoma cells to hydroxycamptothecin.
Topics: Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Humans; Mouth Neoplasms; Nerve Tissue Proteins; RNA, Small Interfering | 2019 |
Two-stage operation for synchronous triple primary cancer of the esophagus, stomach, and ampulla of Vater: report of a case.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Diagnostic Imaging; Digestive System Surgical Procedures; Esophageal Neoplasms; Fatal Outcome; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Plastic Surgery Procedures; Prostatic Neoplasms; Stomach Neoplasms | 2014 |
Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chi-Square Distribution; DNA Damage; Drug Resistance, Neoplasm; Female; Humans; Hydroxyurea; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mouth Neoplasms; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Serine-Threonine Kinases; Radiation Tolerance; RNA Interference; Survival Rate; Time Factors; Transfection; Ultraviolet Rays; Up-Regulation | 2013 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
[A case of recurrence after resection of gastric cancer successfully treated by combination chemotherapy with CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stomach Neoplasms | 2013 |
A novel diagnostic criterion for lymph node metastasis in cervical cancer using multi-detector computed tomography.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Multidetector Computed Tomography; Neoadjuvant Therapy; Organoplatinum Compounds; Precision Medicine; Uterine Cervical Neoplasms | 2013 |
Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; DNA Copy Number Variations; Drug Synergism; ErbB Receptors; Gene Dosage; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2014 |
Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Uterine Cervical Neoplasms | 2015 |
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Retreatment; Treatment Outcome | 2015 |
Vaginal carcinoma in a young woman who underwent fertility-sparing treatment involving chemotherapy and conservative surgery.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Female; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Organoplatinum Compounds; Remission Induction; Uterine Hemorrhage; Vagina; Vaginal Neoplasms | 2015 |
PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Topics: Activation, Metabolic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Polo-Like Kinase 1; Prodrugs; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proteolysis; Proto-Oncogene Proteins; Pteridines; Rhabdomyosarcoma, Embryonal; Sarcoma, Ewing; Skin Neoplasms; Topoisomerase I Inhibitors; Ubiquitination; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2015 |
High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Camptothecin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Complex and Mixed; Neutrophils; Platelet Count; Platinum Compounds; Pneumonectomy; Prognosis; Radiotherapy; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Gamma Rays; Humans; Hysterectomy; Injections, Intravenous; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Survival Analysis; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Apoptotic capacity and risk of squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Alcohol Drinking; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Case-Control Studies; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Lymphocytes; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Risk Factors; Smoking; Squamous Cell Carcinoma of Head and Neck; Topoisomerase I Inhibitors | 2017 |
Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration.
Topics: Administration, Intravenous; Administration, Rectal; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Female; Humans; Hydrogels; Irinotecan; Lipids; Male; Mice, Nude; Nanomedicine; Nanoparticles; Phase Transition; Poloxamer; Rats, Sprague-Dawley; Solubility; Technology, Pharmaceutical; Transition Temperature; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cysteine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forkhead Transcription Factors; Head and Neck Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Organoselenium Compounds; Selenocysteine; Tirapazamine; Triazines; Xenograft Model Antitumor Assays | 2008 |
Apoptotic effect of CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Humans; Mouth Mucosa; Mouth Neoplasms; Peptide Fragments; Proto-Oncogene Proteins c-bcl-2; Submandibular Gland Neoplasms; Tongue Neoplasms; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2009 |
An autopsy case of acute pulmonary toxicity related to irinotecan.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Autopsy; Camptothecin; Carcinoma, Squamous Cell; Fatal Outcome; Humans; Irinotecan; Laryngeal Neoplasms; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasm Staging; Radiography, Thoracic; Respiratory Distress Syndrome; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2008 |
Monitoring of cell death in epithelial cells using high frequency ultrasound spectroscopy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Epithelial Cells; Humans; Laryngeal Neoplasms; Signal Processing, Computer-Assisted; Transducers; Tumor Cells, Cultured; Ultrasonography | 2009 |
Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Synergism; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Peritoneal Neoplasms; Plant Preparations; Prunus; Triterpenes; Xenograft Model Antitumor Assays | 2009 |
Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Topotecan; Xenograft Model Antitumor Assays | 2010 |
ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968.
Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; DNA-Binding Proteins; Female; Humans; Infrared Rays; Ovarian Neoplasms; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Ultraviolet Rays | 2010 |
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Cell Hypoxia; Cysteine; Drug Delivery Systems; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Reactive Oxygen Species; RNA, Small Interfering; Selenocysteine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Male; Middle Aged; Neck Dissection; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Recombinant Proteins; Tongue Neoplasms | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
[Mechanism of combined use of cyclopamine and hydroxycamptothecin in inducing the apoptosis of human oral squamous cell carcinoma cell line].
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; Humans; Mouth Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Veratrum Alkaloids | 2010 |
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy; Survival Rate; Treatment Outcome | 2011 |
[A case of complete resection of a squamous cell lung cancer invading diaphragm after neoadjuvant chemotherapy of nedaplatin and irinotecan].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Diaphragm; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Pneumonectomy | 2010 |
A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Humans; Immunohistochemistry; Lung Neoplasms; Mink; NF-E2-Related Factor 2; Oxidoreductases Acting on Sulfur Group Donors; Peroxiredoxin III; Peroxiredoxins; Prognosis; Reactive Oxygen Species; RNA Interference; Transfection; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Up-Regulation | 2011 |
Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; China; Combined Modality Therapy; Cranial Irradiation; Docetaxel; Endostatins; Exons; Female; Genes, erbB-1; Humans; Incidental Findings; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Pneumonectomy; Recombinant Proteins; Smoking; Taxoids; Young Adult | 2012 |
Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dealkylation; Death-Associated Protein Kinases; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Uterine Cervical Neoplasms | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Fertility-sparing management for bulky cervical cancer using neoadjuvant transuterine arterial chemotherapy followed by vaginal trachelectomy.
Topics: Adult; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Organoplatinum Compounds; Pregnancy; Retrospective Studies; Uterine Artery Embolization; Uterine Cervical Neoplasms; Vagina | 2012 |
Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Azacitidine; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Exodeoxyribonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; RecQ Helicases; RNA, Small Interfering; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms; Werner Syndrome Helicase | 2012 |
Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Fragmentation; HL-60 Cells; Humans; In Situ Nick-End Labeling; Irinotecan; Mouth Neoplasms; Topoisomerase Inhibitors | 2012 |
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Esophageal Neoplasms; Female; Gastrointestinal Diseases; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Treatment Outcome | 2002 |
[Anticancer effect of hydroxycampothecin on oral squamous carcinoma cell line].
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mouth Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
[Inhibition of hydroxycamptothecin on laryngeal squamous carcinoma cell line].
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Disease Models, Animal; Flow Cytometry; Laryngeal Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; S Phase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Upregulation of cystatin M during the progression of oropharyngeal squamous cell carcinoma from primary tumor to metastasis.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Camptothecin; Carcinoma, Squamous Cell; Cathepsin B; Cell Line; Cycloheximide; Cystatin M; Cystatins; Cytotoxicity Tests, Immunologic; Disease Progression; DNA Fragmentation; Enzyme Inhibitors; Humans; Immunohistochemistry; In Situ Hybridization; Lymphatic Metastasis; Male; Middle Aged; Mouth Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha | 2003 |
[Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Deglutition Disorders; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Fluorouracil; Humans; Irinotecan; Kidney Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Prognosis; Tomography, X-Ray Computed | 2003 |
Concurrent radiation therapy and irinotecan in stage IIIB cervical cancer.
Topics: Adult; Camptothecin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiation Dosage; Radiation-Sensitizing Agents; Radiotherapy, High-Energy; Thailand; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Female; Humans; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Male; Microscopy, Confocal; Middle Aged; Prodrugs; Topoisomerase I Inhibitors | 2003 |
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Irinotecan; Kinetics; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2004 |
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organoselenium Compounds; Radiation-Sensitizing Agents; Selenium; Selenocysteine; Selenomethionine; Time Factors | 2004 |
The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.
Topics: Adenovirus E1A Proteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Camptothecin; Carcinoma, Squamous Cell; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; DNA Topoisomerases, Type I; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Irinotecan; Nuclear Proteins; Proto-Oncogene Proteins p21(ras); Repressor Proteins; Tumor Cells, Cultured | 2004 |
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Survival Rate | 2004 |
2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.
Topics: Adenosine Triphosphate; Antimetabolites; Antineoplastic Agents, Phytogenic; Benzimidazoles; Brain Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Deoxyglucose; DNA Damage; Drug Interactions; Enzyme Inhibitors; Etoposide; Glioma; Humans; Radiation-Sensitizing Agents; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2004 |
Suppressive effect of CPT-11 on rat esophageal tumorigenesis induced by N-nitrosomethylbenzylamine.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Dimethylnitrosamine; Disease Models, Animal; DNA, Single-Stranded; Esophageal Neoplasms; Immunohistochemistry; Irinotecan; Male; Precancerous Conditions; Proliferating Cell Nuclear Antigen; Rats; Tumor Suppressor Protein p53 | 2004 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypoxia; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Nude; Microcirculation; Oxygen; Rats; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cysteine; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Organoselenium Compounds; Pharmacogenetics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Selenocysteine; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
[Antitumor effects of ring-closed and ring-opened hydroxycamptothecin on oral squamous carcinoma cell line Tca8113].
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Humans; Lactones; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neoplasm Transplantation | 2005 |
Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Radiation Tolerance; Radiotherapy; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
[Clinical effects of combination chemotherapy with irinotecan hydrochloride and cisplatin on cervical cancer: study of 46 patients].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Hysterectomy; Irinotecan; Middle Aged; Radiotherapy, Adjuvant; Uterine Cervical Neoplasms | 2005 |
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Therapy, Combination; Follow-Up Studies; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Prodrugs; Protein Kinase Inhibitors; Pyridines; Tongue Neoplasms; Treatment Outcome | 2005 |
Identification and immunotherapeutic targeting of antigens induced by chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Base Sequence; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Immunotherapy; Irinotecan; Membrane Proteins; Mice; Mice, Nude; Molecular Sequence Data; Treatment Outcome | 2006 |
Designer combination therapy for cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Delivery Systems; Drug Design; Female; Humans; Immunotherapy; Irinotecan; Membrane Proteins; Mice; Mice, Nude; Treatment Outcome | 2006 |
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiog
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cysteine; Down-Regulation; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Organoselenium Compounds; Selenocysteine; Transplantation, Heterologous | 2006 |
Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Topics: Antigens, CD20; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; CD40 Antigens; Cell Survival; Clone Cells; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Fluorouracil; Humans; Integrin alpha1; Integrin alpha6; Irinotecan; Mitomycin; Uterine Cervical Neoplasms; X-Rays | 2006 |
[Collision cancer of squamous cell carcinoma and small cell carcinoma of the lung; report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Pneumonectomy | 2006 |
Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Irinotecan; Male; Neoadjuvant Therapy; Remission Induction; Urinary Bladder Neoplasms | 2006 |
Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Gallbladder Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2006 |
[Superficial small cell carcinoma of esophagus treated by endoscopic mucosal resection combined with chemoradiotherapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Esophagoscopes; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Mucous Membrane | 2007 |
Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Female; Humans; Irinotecan; Middle Aged; Tomography, X-Ray Computed | 2007 |
Antitumor effects of hydroxycamptothecin-loaded poly[ethylene glycol]-poly [gamma-benzyl-L-glutamate] micelles against oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cheek; Cricetinae; Female; Humans; Inhibitory Concentration 50; Male; Micelles; Mouth Mucosa; Mouth Neoplasms; Particle Size; Polyethylene Glycols; Polyglutamic Acid; Tongue Neoplasms | 2007 |
Experimental evidence for the efficacy of combined therapy of CPT-11 and hyperthermia for squamous cell carcinoma of the esophagus.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Humans; Hyperthermia, Induced; Irinotecan | 2007 |
[A case of multidrug-resistant squamous cell lung carcinoma responding to S-1 plus CPT-11 combination chemotherapy].
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Drug Combinations; Drug Resistance, Neoplasm; Humans; Irinotecan; Keratin-19; Keratins; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Caspase 3; DNA Damage; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Burkitt Lymphoma; Camptothecin; Carcinoma, Squamous Cell; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Mice, Nude; Reproducibility of Results; Tumor Cells, Cultured | 1995 |
Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Humans; Irinotecan; Tongue Neoplasms; Tumor Cells, Cultured | 1995 |
Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Humans; Injections, Intraperitoneal; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 1993 |
Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance; Fibrosarcoma; Head and Neck Neoplasms; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred C3H; Topotecan; Tumor Cells, Cultured | 1993 |
Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Topics: Antibiotics, Antineoplastic; Benz(a)Anthracenes; Camptothecin; Carcinoma, Squamous Cell; Dactinomycin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Enzyme Induction; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; KB Cells; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1996 |
[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
Clonal analysis of cancer cells that survived anticancer drug treatment.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1997 |
[A case of relapsed thymic carcinoma that responded remarkably to chemotherapy with CPT-11].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Humans; Irinotecan; Male; Middle Aged; Thymus Neoplasms | 1998 |
[Evaluation of antitumor activity of etoposide administered orally for 21 consecutive days against human uterine cancer subcutaneous and/or orthotopic xenografts in nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Floxuridine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Skin; Transplantation, Heterologous; Uterine Neoplasms | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Mice; Mice, Nude; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Tumor Cells, Cultured | 2000 |
Impact on survival following successful neoadjuvant chemotherapy and radical surgery for Stage IIb bulky and Stage IIIb cervical cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Peplomycin; Uterine Cervical Neoplasms | 2001 |
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |
[An early phase II study of CPT-11 in primary lung cancer].
Topics: Adenocarcinoma; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 1991 |
Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Injections, Intravenous; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 1991 |